January 2020 in “Current trends in diagnosis & treatment”
The review suggests doctors should carefully weigh risks and benefits of off-label drug use, involve patients in decisions, and calls for better regulations and monitoring.
8 citations
,
August 2018 in “International Journal of Dermatology”
The document concludes that doctors should carefully consider off-label drug use in dermatology and always inform patients, while more research is needed on the safety and effectiveness of such practices.
The conversation provides a six-step guide on how to get a prescription for oral minoxidil (OM) for hair loss by finding a supportive dermatologist, even if they are not local, and preparing a case for its use during a virtual consultation. The guide emphasizes the importance of research, insurance considerations, and the potential for initial hair shedding with OM treatment.
Dutasteride is less commonly prescribed for hair loss because it is not FDA-approved for this purpose, unlike finasteride, which is more accessible and preferred due to fewer side effects. Dutasteride may be more effective in reducing DHT but has a longer half-life and potentially more significant side effects.
A 26-year-old has seen hair improvement after 18 months on finasteride, with no side effects, and is considering switching to dutasteride despite difficulty obtaining a prescription. They also use dermastamping and are hesitant to try minoxidil, preferring to explore dutasteride first.
Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.
Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.